ProxyMiner / Company

PFIZER INCPFE

Latest proxy: 2026 · view on SEC ↗ · CIK 0000078003

CEO total pay

$27,585,301

A. Bourla · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

Item 402(u)

277 to 1

Item 402(u) section may live outside the CD&A

Compensation committee

CD&A

Compensation Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
A. Bourla2025 compensation
Chairman and Chief Executive Officer
$27,585,301 12%
86% at-risk
$1,800,000$9,442,705$5,400,000$1,940,441
D. Denton2025 compensation
Chief Financial Officer, EVP
$9,670,182 19%
79% at-risk
$1,388,964$2,367,893$2,800,000$613,840
C. Boshoff2025 compensation
Chief Scientific Officer and President, Research & Development
$10,006,039 27%
80% at-risk
$1,400,000$1,808,655$3,150,000$648,006
A. Malik2025 compensation
Chief U.S. Commercial Officer, EVP
$9,429,227 14%
79% at-risk
$1,386,817$2,281,630$2,900,000$611,245
D. Lankler2025 compensation
Chief Legal Officer, EVP
$9,106,276
78% at-risk
$1,411,787$1,976,390$2,675,000$535,588

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

This Compensation Discussion and Analysis (CD&A) describes Pfizer’s executive compensation program for 2025 and certain elements of our 2026 program. It explains how the Compensation Committee of the Board (the Committee) made 2025 performance year compensation decisions for our executives, including the following Named Executive Officers (NEOs): Albert Bourla, DVM, Ph.D. — Chairman and Chief Executive Officer (CEO) David M. Denton — Chief Financial Officer (CFO), Executive Vice President (EVP) Chris Boshoff, MD, FRCP, FMedSci, Ph.D. — Chief Scientific Officer and President, Research & Development Aamir Malik — Chief U.S. Commercial Officer, Executive Vice President (EVP) Douglas M. Lankler — Chief Legal Officer, Executive Vice President (EVP) Executive Summary54Pfizer’s Executive Compensation: Pay-for-Performance Philosophy57Advisory Vote on Executive Compensation and Shareholder Outreach Program 60Executive Compensation Program SummarySection 1: Elements of Our Executive Compensation Program62Description of NEO Pay Elements 672026 Compensation ActionsSection 2: How We Determine Executive Compensation68Overview of the Role of the Compensation Committee and its Independent Compensa

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    It also prohibits trading in puts, calls, straddles, equity swaps, or other derivative securities, including exchange funds, that are directly linked to our common stock (sometimes referred to as “hedging”)

  • pledging

    prohibited

    Consistent with our policy prohibiting the pledging of Pfizer stock, none of our NEOs or other executive officers have pledged Pfizer stock as collateral for personal loans or other obligations.

  • clawback

    present

    clawback policy, which complies with the SEC rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act and NYSE rules, provides that Pfizer will seek recovery, in the event of a required accounting restat

  • stock ownership guidelines

    present

    stock ownership guidelines promote alignment with shareholders’ interest by requiring the CEO to own Pfizer stock with a value equal to at least eight times his base salary and for each other NEO to own Pfizer stock with

  • change in control

    What We DoWhat We Do Not Do 100% Performance-Based Annual Long-Term Incentives Permit Hedging or Pledging of Pfizer Stock Minimum Vesting Period on Long-Term Incentives Provide Employment Agreements Non-Compete Agreements Provide “Single Trigger” Change in Control Payments or Ben

    What We DoWhat We Do Not Do 100% Performance-Based Annual Long-Term Incentives Permit Hedging or Pledging of Pfizer Stock Minimum Vesting Period on Long-Term Incentives Provide Employment Agreements Non-Compete Agreement

  • compensation consultant

    independent

    independent compensation consultant

  • compensation committee

    Compensation Committee

    CSI designations are ultimately reviewed by the Compensation Committee and the Board of Directors as part of their review of the financial statements

Performance markers

Metric facts

  • revenue

    $1.2 billion

    is the result of a comprehensive business review and the development of goals from the bottom-up. This process ensures that targets are sufficiently rigorous based on all known factors for a given year. As such, targets

  • ceo pay ratio

    277 to 1

    CEO PAY RATIO The 2025 annual total compensation for Dr. Bourla was 277 times the annual total compensation of the median-paid employee as follows: Annual Total CompensationAlbert Bourla$27,585,301 (1)Median-Paid Employe

Ask

Anything about PFIZER INC’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…